Consideration of Metal Organic Frameworks for Respiratory Delivery
Source abstract
Abstract
Metal organic frameworks (MOFs) have garnered increased attention over the past 20 years. Due to their porosity, high surface area, and nearly limitless customization and tunability MOFs have been designed for applications ranging from gas storage and separation to catalysis to sensing to biomedical engineering. Within the latter category, MOFs offer an appealing function for drug delivery as they can be loaded with multiple therapeutic moieties tailored to target specific disorders with triggered and controlled release characteristics. However, there is an unmet need to assess their viability for pulmonary treatment via inhalation. Targeting pulmonary disorders including infectious diseases by delivering medication directly to the lungs attacks the primary site of infection rather than relying on systemic distribution. The inherent advantage of this strategy is maximizing local lung concentrations of the drug. An introduction to inhaled therapies is provided here as a preamble to a brief summary of the current development state of MOF drug delivery systems. This review is intended to highlight the relative disparity between research toward MOFs as pulmonary drug delivery vehicles compared to other delivery platforms. Prospective biomedical applications for inhalable MOFs are also discussed.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Metal-Organic Frameworks: Synthesis and Applications · Gas Sensing Nanomaterials and Sensors · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for Engineered Systems, RTI International, USA
Center for Analytical Chemistry and Pharmaceutics, RTI International, USA
References (100+)
Show source-provided references
1. Abuçafy M.P., Caetano B.L., Chiari-Andréo B.G., Fonseca-Santos B., do Santos A.M., Chorilli M., Chiavacci L.A., Supramolecular cyclodextrin-based metal-organic frameworks as efficient carrier for anti-inflammatory drugs, European Journal of Pharmaceutics and Biopharmaceutics, 127 (2018) 112–119. DOI: 10.1016/j.ejpb.2018.02.00910.1016/j.ejpb.2018.02.009 ↗
2. Adi H., Young P.M., Chan H.-K., Salama R., Traini D., Controlled release antibiotics for dry powder lung delivery, Drug Development and Industrial Pharmacy, 36 (2010) 119–126. DOI: 10.3109/0363904090309976910.3109/03639040903099769 ↗
3. Agent P., Parrott H., Inhaled therapy in cystic fibrosis: Agents, devices and regimens, Breathe (Sheffield, England), 11 (2015) 110–118. DOI: 10.1183/20734735.02101410.1183/20734735.021014 ↗
4. Alangari A.A., Corticosteroids in the treatment of acute asthma, Annals of Thoracic Medicine, 9 (2014) 187–192. DOI: 10.4103/1817-1737.14012010.4103/1817-1737.140120 ↗
5. Allahverdiyev A.M., Abamor E.S., Bagirova M., Rafailovich M., Antimicrobial effects of TiO2 and Ag2O nanoparticles against drug-resistant bacteria and Leishmania parasites, Future Microbiology, 6 (2011) 933–940. DOI: 10.2217/fmb.11.7810.2217/fmb.11.78 ↗
6. Avci-Camur C., Troyano J., Pérez-Carvajal J., Legrand A., Farrusseng D., Imaz I., Maspoch D., Aqueous production of spherical Zr-MOF beads via continuous-flow spray-drying, Green Chemistry, 20 (2018) 873–878. DOI: 10.1039/C7GC03132G10.1039/C7GC03132G ↗
7. Baghel S., Cathcart H., O’Reilly N.J., Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs, Journal of Pharmaceutical Sciences, 105 (2016) 2527–2544. DOI: 10.1016/j.xphs.2015.10.00810.1016/j.xphs.2015.10.008 ↗
8. Baker C., Pradhan A., Pakstis L., Pochan D.J., Shah S.I., Synthesis and antibacterial properties of silver nanoparticles, Journal of Nanoscience and Nanotechnology, 5 (2005) 244–249. DOI: 10.1166/jnn.2005.03410.1166/jnn.2005.034 ↗
9. Banaschewski B., Hofmann T., Inhaled antibiotics for mycobacterial lung disease, Pharmaceutics, 11 (2019) 352. DOI: 10.3390/pharmaceutics1107035210.3390/pharmaceutics11070352 ↗
10. Beg S., Rahman M., Jain A., Saini S., Midoux P., Pichon C., Ahmad F.J., Akhter S., Nanoporous metal organic frameworks as hybrid polymer–metal composites for drug delivery and biomedical applications, Drug Discovery Today, 22 (2017) 625–637. DOI: 10.1016/j.drudis.2016.10.00110.1016/j.drudis.2016.10.001 ↗
11. Bian R., Wang T., Zhang L., Li L., Wang C., A combination of tri-modal cancer imaging and in vivo drug delivery by metal–organic framework based composite nanoparticles, Biomaterials Science, 3 (2015) 1270–1278. DOI: 10.1039/C5BM00186B10.1039/C5BM00186B ↗
12. Bierkandt F.S., Leibrock L., Wagener S., Laux P., Luch A., The impact of nanomaterial characteristics on inhalation toxicity, Toxicology Research, 7 (2018) 321–346. DOI: 10.1039/c7tx00242d10.1039/C7TX00242D ↗
13. Biggs D.L., Lengsfeld C.S., Hybertson B.M., Ng K.-y., Manning M.C., Randolph T.W., In vitro and in vivo evaluation of the effects of PLA microparticle crystallinity on cellular response, Journal of Controlled Release, 92 (2003) 147–161. DOI: 10.1016/s0168-3659(03)00325-010.1016/S0168-3659(03)00325-0 ↗
14. Borghardt J.M., Kloft C., Sharma A., Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes, Canadian Respiratory Journal, 2018 (2018) 2732017. DOI: 10.1155/2018/273201710.1155/2018/2732017 ↗
15. Borkow G., Gabbay J., Copper as a biocidal tool, Current Medicinal Chemistry, 12 (2005) 2163–2175. DOI: 10.2174/092986705463761710.2174/0929867054637617 ↗
16. Borm P.J.A., Robbins D., Haubold S., Kuhlbusch T., Fissan H., Donaldson K., Schins R., Stone V., Kreyling W., Lademann J., Krutmann J., Warheit D., Oberdorster E., The potential risks of nanomaterials: a review carried out for ECETOC, Particle and Fibre Toxicology, 3 (2006) 11. DOI: 10.1186/1743-8977-3-1110.1186/1743-8977-3-11 ↗
17. Bosquillon C., Lombry C., Préat V., Vanbever R., Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance, Journal of Controlled Release, 70 (2001) 329–339. DOI: 10.1016/S0168-3659(00)00362-X10.1016/S0168-3659(00)00362-X ↗
18. Braunstein M., Hickey A.J., Ekins S., Why wait? The case for treating tuberculosis with inhaled drugs, Pharmaceutical Research, 36 (2019) 166. DOI: 10.1007/s11095-019-2704-610.1007/s11095-019-2704-6 ↗
19. Breasted J.H., The Edwin Smith Surgical Papyrus: published in facsimile and hieroglyphic transliteration with translation and commentary in two volumes, Chic. UP, 1930, ISBN: 0918986737.
20. Bright K.R., Sicairos-Ruelas E.E., Gundy P.M., Gerba C.P., Assessment of the antiviral properties of zeolites containing metal ions, Food and Environmental Virology, 1 (2008) 37. DOI: 10.1007/s12560-008-9006-110.1007/s12560-008-9006-1 ↗
21. Byron P.R., Hindle M., Lange C.F., Longest P.W., McRobbie D., Oldham M.J., Olsson B., Thiel C.G., Wachtel H., Finlay W.H., In vivo–in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols, Journal of Aerosol Medicine and Pulmonary Drug Delivery, 23 (2010) S-59–S-69. DOI: 10.1089/jamp.2010.084610.1089/jamp.2010.0846 ↗
22. Carne-Sanchez A., Imaz I., Cano-Sarabia M., Maspoch D., A spray-drying strategy for synthesis of nanoscale metal-organic frameworks and their assembly into hollow superstructures, Nature Chemistry, 5 (2013) 203–211. DOI: 10.1038/nchem.156910.1038/nchem.1569 ↗
23. Champion J.A., Walker A., Mitragotri S., Role of particle size in phagocytosis of polymeric microspheres, Pharmaceutical Research, 25 (2008) 1815–1821. DOI: 10.1007/s11095-008-9562-y10.1007/s11095-008-9562-y ↗
24. Chang E.L., Simmers C., Knight D.A., Cobalt complexes as antiviral and antibacterial agents, Pharmaceuticals, 3 (2010) 1711–1728. DOI: 10.3390/ph306171110.3390/ph3061711 ↗
25. Chao A., Sieminski P.J., Owens C.P., Goulding C.W., Iron acquisition in mycobacterium tuberculosis, Chemical Reviews, 119 (2019) 1193–1220. DOI: 10.1021/acs.chemrev.8b0028510.1021/acs.chemrev.8b00285 ↗
26. Chen C.-W., Hsu C.-Y., Lai S.-M., Syu W.-J., Wang T.-Y., Lai P.-S., Metal nanobullets for multidrug resistant bacteria and biofilms, Advanced Drug Delivery Reviews, 78 (2014) 88–104. DOI: 10.1016/j.addr.2014.08.00410.1016/j.addr.2014.08.004 ↗
27. Chen T.-T., Yi J.-T., Zhao Y.-Y., Chu X., Biomineralized metal–organic framework nanoparticles enable intracellular delivery and endo-lysosomal release of native active proteins, Journal of the American Chemical Society, 140 (2018) 9912–9920. DOI: 10.1021/jacs.8b0445710.1021/jacs.8b04457 ↗
28. Chen W., Wu C., Synthesis, functionalization, and applications of metal–organic frameworks in biomedicine, Dalton Transactions, 47 (2018) 2114–2133. DOI: 10.1039/C7DT04116K10.1039/C7DT04116K ↗
29. Chen Y., Li P., Modica J.A., Drout R.J., Farha O.K., Acid-resistant mesoporous metal–organic framework toward oral insulin delivery: protein encapsulation, protection, and release, Journal of the American Chemical Society, 140 (2018) 5678–5681. DOI: 10.1021/jacs.8b0208910.1021/jacs.8b02089 ↗
30. Clement J.L., Jarrett P.S., Antibacterial silver, Metal-Based Drugs, 1 (1994) 467–482. DOI: 10.1155/MBD.1994.46710.1155/MBD.1994.467 ↗
31. Cook R.O., Pannu R.K., Kellaway I.W., Novel sustained release microspheres for pulmonary drug delivery, Journal of Controlled Release, 104 (2005) 79–90. DOI: 10.1016/j.jconrel.2005.01.00310.1016/j.jconrel.2005.01.003 ↗
32. Corma A., García H., Llabrés i Xamena F.X., Engineering metal organic frameworks for heterogeneous catalysis, Chemical Reviews, 110 (2010) 4606–4655. DOI: 10.1021/cr900392410.1021/cr9003924 ↗
33. Coronado E., Giménez-Marqués M., Martí-Gastaldo C., Espallargas G.M., Navarro-Moratalla E., Waerenborgh J.C., Hybrid magnetic superconductors formed by TaS2 layers and spin crossover complexes, Inorganic Chemistry, 52 (2013) 8451–8460. DOI: 10.1021/ic400320g10.1021/ic400320g ↗
34. Crowder T.M., Rosati J.A., Schroeter J.D., Hickey A.J., Martonen T.B., Fundamental effects of particle morphology on lung delivery: predictions of Stokes’ law and the particular relevance to dry powder inhaler formulation and development, Pharmaceutical Research, 19 (2002) 239–245. DOI: 10.1023/A:101442653093510.1023/A:1014426530935 ↗
35. Davies L.A., Nunez-Alonso G.A., McLachlan G., Hyde S.C., Gill D.R., Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy, Human Gene Therapy Clinical Development, 25 (2014) 97–107. DOI: 10.1089/humc.2014.01910.1089/humc.2014.019 ↗
36. De Boer A.H., Hagedoorn P., Hoppentocht M., Buttini F., Grasmeijer F., Frijlink H.W., Dry powder inhalation: past, present and future, Expert Opinion on Drug Delivery, 14 (2017) 499–512. DOI: 10.1080/17425247.2016.122484610.1080/17425247.2016.1224846 ↗
37. DeCarlo P.F., Slowik J.G., Worsnop D.R., Davidovits P., Jimenez J.L., Particle morphology and density characterization by combined mobility and aerodynamic diameter measurements. Part 1: Theory, Aerosol Science and Technology, 38 (2004) 1185–1205. DOI: 10.1080/02786829090390710.1080/027868290903907 ↗
38. Della Rocca J., Liu D., Lin W., Nanoscale metal–organic frameworks for biomedical imaging and drug delivery, Accounts of Chemical Research, 44 (2011) 957–968. DOI: 10.1021/ar200028a10.1021/ar200028a ↗
39. Dharmadhikari A.S., Kabadi M., Gerety B., Hickey A.J., Fourie P.B., Nardell E., Phase I, Single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis, Antimicrobial Agents and Chemotherapy, 57 (2013) 2613–2619. DOI: 10.1128/aac.02346-1210.1128/AAC.02346-12 ↗
40. Ding M., Cai X., Jiang H.-L., Improving MOF stability: approaches and applications, Chemical Science, 10 (2019) 10209–10230. DOI: 10.1039/C9SC03916C10.1039/C9SC03916C ↗
41. Dobry D.E., Settell D.M., Baumann J.M., Ray R.J., Graham L.J., Beyerinck R.A., A model-based methodology for spray-drying process development, Journal of Pharmaceutical Innovation, 4 (2009) 133–142. DOI: 10.1007/s12247-009-9064-410.1007/s12247-009-9064-4 ↗
42. Donaldson K., Brown D., Clouter A., Duffin R., MacNee W., Renwick L., Tran L., Stone V., The pulmonary toxicology of ultrafine particles, Journal of Aerosol Medicine, 15 (2002) 213–220. DOI: 10.1089/08942680232028233810.1089/089426802320282338 ↗
43. Dunber C.A., Hickey A.J., Holzner P., Dispersion and characterization of pharmaceutical dry powder aerosols, KONA Powder and Particle Journal, 16 (1998) 7–45. DOI: 10.14356/kona.199800710.14356/kona.1998007 ↗
44. Durham P.G., Young E.F., Braunstein M.S., Welch J.T., Hickey A.J., A dry powder combination of pyrazinoic acid and its n-propyl ester for aerosol administration to animals, International Journal of Pharmaceutics, 514 (2016) 384–391. DOI: 10.1016/j.ijpharm.2016.04.06310.1016/j.ijpharm.2016.04.063 ↗
45. Durham P.G., Zhang Y., German N., Mortensen N., Dhillon J., Mitchison D.A., Fourie P.B., Hickey A.J., Spray dried aerosol particles of pyrazinoic acid salts for tuberculosis therapy, Molecular Pharmaceutics, 12 (2015) 2574–2581. DOI: 10.1021/acs.molpharmaceut.5b0011810.1021/acs.molpharmaceut.5b00118 ↗
46. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., Mintzes J., Deaver D., Lotan N., Langer R., Large porous particles for pulmonary drug delivery, Science, 276 (1997) 1868–1872. DOI: 10.1126/science.276.5320.186810.1126/science.276.5320.1868 ↗
47. Eldridge J.A., Repko D., Mumper R.J., Retention of polyphenolic species in spray-dried blackberry extract using mannitol as a thermoprotectant, Journal of Medicinal Food, 17 (2014) 1064–1069. DOI: 10.1089/jmf.2013.017710.1089/jmf.2013.0177 ↗
48. Ellis T., Chiappi M., García-Trenco A., Al-Ejji M., Sarkar S., Georgiou T.K., Shaffer M.S.P., Tetley T.D., Schwander S., Ryan M.P., Porter A.E., Multimetallic microparticles increase the potency of rifampicin against intracellular mycobacterium tuberculosis, ACS Nano, 12 (2018) 5228–5240. DOI: 10.1021/acsnano.7b0826410.1021/acsnano.7b08264 ↗
49. Fernández-Paz C., Rojas S., Salcedo-Abraira P., Simón-Yarza T., Remuñán-López C., Horcajada P., Metal–organic framework microsphere formulation for pulmonary administration, ACS Applied Materials & Interfaces, 12 (2020) 25676–25682. DOI: 10.1021/acsami.0c0735610.1021/acsami.0c07356 ↗
50. Festa R.A., Helsel M.E., Franz K.J., Thiele D.J., Exploiting innate immune cell activation of a copper-dependent antimicrobial agent during infection, Chemistry & Biology, 21 (2014) 977–987. DOI: 10.1016/j.chembiol.2014.06.00910.1016/j.chembiol.2014.06.009 ↗
51. Foldbjerg R., Dang D.A., Autrup H., Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549, Archives of Toxicology, 85 (2011) 743–750. DOI: 10.1007/s00204-010-0545-510.1007/s00204-010-0545-5 ↗
52. Franz K.J., Metzler-Nolte N., Introduction: metals in medicine, Chemical Reviews, 119 (2019) 727–729. DOI: 10.1021/acs.chemrev.8b0068510.1021/acs.chemrev.8b00685 ↗
53. Frijlink H.W., De Boer A.H., Dry powder inhalers for pulmonary drug delivery, Expert Opinion on Drug Delivery, 1 (2004) 67–86. DOI: 10.1517/17425247.1.1.6710.1517/17425247.1.1.67 ↗
54. Garrastazu Pereira G., Lawson A.J., Buttini F., Sonvico F., Loco-regional administration of nanomedicines for the treatment of lung cancer, Drug Delivery, 23 (2016) 2881–2896. DOI: 10.3109/10717544.2015.111404710.3109/10717544.2015.1114047 ↗
55. Garzón-Tovar L., Cano-Sarabia M., Carné-Sánchez A., Carbonell C., Imaz I., Maspoch D., A spray-drying continuous-flow method for simultaneous synthesis and shaping of microspherical high nuclearity MOF beads, Reaction Chemistry & Engineering, 1 (2016) 533–539. DOI: 10.1039/C6RE00065G10.1039/C6RE00065G ↗
56. Gharse S., Fiegel J., Large porous hollow particles: lightweight champions of pulmonary drug delivery, Current Pharmaceutical Design, 22 (2016) 2463–2469. accessed 02.07.2020.10.2174/1381612822666160128145356 ↗
57. Giachi G., Pallecchi P., Romualdi A., Ribechini E., Lucejko J.J., Colombini M.P., Mariotti Lippi M., Ingredients of a 2,000-y-old medicine revealed by chemical, mineralogical, and botanical investigations, Proceedings of the National Academy of Sciences, 110 (2013) 1193–1196. DOI: 10.1073/pnas.121677611010.1073/pnas.1216776110 ↗
58. Giljohann D.A., Seferos D.S., Daniel W.L., Massich M.D., Patel P.C., Mirkin C.A., Gold nanoparticles for biology and medicine, Angewandte Chemie International Edition, 49 (2010) 3280–3294. DOI: 10.1002/anie.20090435910.1002/anie.200904359 ↗
59. Giménez-Marqués M., Hidalgo T., Serre C., Horcajada P., Nanostructured metal–organic frameworks and their bio-related applications, Coordination Chemistry Reviews, 307 (2016) 342–360. DOI: 10.1016/j.ccr.2015.08.00810.1016/j.ccr.2015.08.008 ↗
60. González-Juarrero M., O’Sullivan M.P., Optimization of inhaled therapies for tuberculosis: The role of macrophages and dendritic cells, Tuberculosis, 91 (2011) 86–92. DOI: 10.1016/j.tube.2010.08.00710.1016/j.tube.2010.08.007 ↗
61. Gordon M.S., Clark A., Brewer T.K., Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients, US Patent, (2000) US6077543A.
62. Grass G., Rensing C., Solioz M., Metallic copper as an antimicrobial surface, Applied and Environmental Microbiology, 77 (2011) 1541–1547. DOI: 10.1128/AEM.02766-1010.1128/AEM.02766-10 ↗
63. Guo A., Durymanov M., Permyakova A., Sene S., Serre C., Reineke J., Metal organic framework (MOF) particles as potential bacteria-mimicking delivery systems for infectious diseases: characterization and cellular internalization in alveolar macrophages, Pharmaceutical Research, 36 (2019) 53. DOI: 10.1007/s11095-019-2589-410.1007/s11095-019-2589-4 ↗
64. Guo Z., Sadler P.J., Metals in medicine, Angewandte Chemie International Edition, 38 (1999) 1512–1531. DOI: 10.1002/(sici)1521-3773(19990601)38:11<1512::Aid-anie1512>3.0.Co;2-y10.1002/(SICI)1521-3773(19990601)38:11<1512::AID-ANIE1512>3.0.CO;2-Y ↗
65. He C.,Liu D., Lin W., Nanomedicine applications of hybrid nanomaterials built from metal–ligand coordination bonds: nanoscale metal–organic frameworks and nanoscale coordination polymers, Chemical Reviews, 115 (2015b) 11079–11108. DOI: 10.1021/acs.chemrev.5b0012510.1021/acs.chemrev.5b00125 ↗
66. He H.,Sun Q., Gao W., Perman J.A., Sun F., Zhu G., Aguila B., Forrest K., Space B., Ma S., A stable metal-organic framework featuring a local buffer environment for carbon dioxide fixation, Angewandte Chemie International Edition, 57 (2018) 4657–4662. DOI: 10.1002/anie.20180112210.1002/anie.201801122 ↗
67. He X.,Wang W.-N., Rational design of efficient semiconductor-based photocatalysts via microdroplets: a review, KONA Powder and Particle Journal, 36 (2019) 201–214. DOI: 10.14356/kona.201901410.14356/kona.2019014 ↗
68. Henry R.R., Mudaliar S.R.D., Howland W.C.III, Chu N., Kim D., An B., Reinhardt R.R., Inhaled insulin using the AERx insulin diabetes management system in healthy and asthmatic subjects, Diabetes Care, 26 (2003) 764–769. DOI: 10.2337/diacare.26.3.76410.2337/diacare.26.3.764 ↗
69. Hickey A.J., Durham P.G., Dharmadhikari A., Nardell E.A., Inhaled drug treatment for tuberculosis: past progress and future prospects, Journal of Controlled Release, 240 (2016a) 127–134. DOI: 10.1016/j.jconrel.2015.11.01810.1016/j.jconrel.2015.11.018 ↗
70. Hickey A.J., Complexity in pharmaceutical powders for inhalation: a perspective, KONA Powder and Particle Journal, 35 (2018) 3–13. DOI: 10.14356/kona.201800710.14356/kona.2018007 ↗
71. Hickey A.J., Edwards D.A., Density and shape factor terms in stokes’ equation for aerodynamic behavior of aerosols, Journal of Pharmaceutical Sciences, 107 (2018) 794–796. DOI: 10.1016/j.xphs.2017.11.00510.1016/j.xphs.2017.11.005 ↗
72. Hickey A.J., Stewart I.E., Jones A., Why we need to deliver large amounts of powder to the lungs and the concurrent challenges, Journal of Aerosol Medicine and Pulmonary Drug Delivery, (2020) A22 (4pp). accessed 02.07.2020.
73. Hofmann W., Modelling inhaled particle deposition in the human lung—a review, Journal of Aerosol Science, 42 (2011) 693–724. DOI: 10.1016/j.jaerosci.2011.05.00710.1016/j.jaerosci.2011.05.007 ↗
74. Horcajada P., Gref R., Baati T., Allan P.K., Maurin G., Couvreur P., Férey G., Morris R.E., Serre C., Metal–organic frameworks in biomedicine, Chemical Reviews, 112 (2012) 1232–1268. DOI: 10.1021/cr200256v10.1021/cr200256v ↗
75. Horcajada P., Serre C., Maurin G., Ramsahye N.A., Balas F., Vallet-Regí M., Sebban M., Taulelle F., Férey G., Flexible porous metal-organic frameworks for a controlled drug delivery, Journal of the American Chemical Society, 130 (2008) 6774–6780. DOI: 10.1021/ja710973k10.1021/ja710973k ↗
76. Horcajada P., Serre C., Vallet-Regí M., Sebban M., Taulelle F., Férey G., Metal–organic frameworks as efficient materials for drug delivery, Angewandte Chemie International Edition, 45 (2006) 5974–5978. DOI: 10.1002/anie.20060187810.1002/anie.200601878 ↗
77. Hu X.,Wang C., Wang L., Liu Z., Wu L., Zhang G., Yu L., Ren X., York P., Sun L., Zhang J., Li H., Nanoporous CD-MOF particles with uniform and inhalable size for pulmonary delivery of budesonide, International Journal of Pharmaceutics, 564 (2019) 153–161. DOI: 10.1016/j.ijpharm.2019.04.03010.1016/j.ijpharm.2019.04.030 ↗
78. Huaizhi Z., Yuantao N., China’s ancient gold drugs, Gold Bulletin, 34 (2001) 24–29. DOI: 10.1007/BF0321480510.1007/BF03214805 ↗
79. Ibrahim M., Verma R., Garcia-Contreras L., Inhalation drug delivery devices: technology update, Medical Devices: Evidence and Research, 8 (2015) 131–139. DOI: 10.2147/MDER.S4888810.2147/MDER.S48888 ↗
80. Jefferson T., Demicheli V., Rivetti D., Jones M., Di Pietrantonj C., Rivetti A., Antivirals for influenza in healthy adults: systematic review, The Lancet, 367 (2006) 303–313. DOI: 10.1016/S0140-6736(06)67970-110.1016/S0140-6736(06)67970-1 ↗
81. Ju Y., Cortez-Jugo C., Chen J., Wang T.-Y., Mitchell A.J., Tsantikos E., Bertleff-Zieschang N., Lin Y.-W., Song J., Cheng Y., Mettu S., Rahim M.A., Pan S., Yun G., Hibbs M.L., et al.., Engineering of nebulized metal–phenolic capsules for controlled pulmonary deposition, Advanced Science, 7 (2020) 1902650. DOI: 10.1002/advs.20190265010.1002/advs.201902650 ↗
82. Kemp I.C., Hartwig T., Herdman R., Hamilton P., Bisten A., Bermingham S., Spray drying with a two-fluid nozzle to produce fine particles: atomization, scale-up, and modeling, Drying Technology, 34 (2016) 1243–1252. DOI: 10.1080/07373937.2015.110374810.1080/07373937.2015.1103748 ↗
83. Kleinstreuer C., Zhang Z., Donohue J.F., Targeted drug-aerosol delivery in the human respiratory system, Annual Review of Biomedical Engineering, 10 (2008) 195–220. DOI: 10.1146/annurev.bioeng.10.061807.16054410.1146/annurev.bioeng.10.061807.160544 ↗
84. Kreno L.E., Leong K., Farha O.K., Allendorf M., Van Duyne R.P., Hupp J.T., Metal–organic framework materials as chemical sensors, Chemical Reviews, 112 (2012) 1105–1125. DOI: 10.1021/cr200324t10.1021/cr200324t ↗
85. Labiris N.R., Dolovich M.B., Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications, British Journal of Clinical Pharmacology, 56 (2003) 588–599. DOI: 10.1046/j.1365-2125.2003.01892.x10.1046/j.1365-2125.2003.01892.x ↗
86. Ladomersky E., Petris M.J., Copper tolerance and virulence in bacteria, Metallomics, 7 (2015) 957–964. DOI: 10.1039/c4mt00327f10.1039/C4MT00327F ↗
87. Laube B.L., The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination, Respiratory Care, 50 (2005) 1161–1176. accessed 02.07.2020.
88. Laube B.L., Aerosolized medications for gene and peptide therapy, Respiratory Care, 60 (2015) 806–824. DOI: 10.4187/respcare.0355410.4187/respcare.03554 ↗
89. Lee W.-H., Loo C.-Y., Traini D., Young P.M., Inhalation of nanoparticle-based drug for lung cancer treatment: advantages and challenges, Asian Journal of Pharmaceutical Sciences, 10 (2015) 481–489. DOI: 10.1016/j.ajps.2015.08.00910.1016/j.ajps.2015.08.009 ↗
90. Lemire J.A., Harrison J.J., Turner R.J., Antimicrobial activity of metals: mechanisms, molecular targets and applications, Nature Reviews Microbiology, 11 (2013) 371–384. DOI: 10.1038/nrmicro302810.1038/nrmicro3028 ↗
91. Liang Z., Yang Z., Yuan H., Wang C., Qi J., Liu K., Cao R., Zheng H., A protein@metal–organic framework nanocomposite for pH-triggered anticancer drug delivery, Dalton Transactions, 47 (2018) 10223–10228. DOI: 10.1039/C8DT01789A10.1039/C8DT01789A ↗
92. Lipworth B.J., Pharmacokinetics of inhaled drugs, British Journal of Clinical Pharmacology, 42 (1996) 697–705. DOI: 10.1046/j.1365-2125.1996.00493.x10.1046/j.1365-2125.1996.00493.x ↗
93. Luz I., Llabrés i Xamena F.X., Corma A., Bridging homogeneous and heterogeneous catalysis with MOFs: “click” reactions with Cu-MOF catalysts, Journal of Catalysis, 276 (2010) 134–140. DOI: 10.1016/j.jcat.2010.09.01010.1016/j.jcat.2010.09.010 ↗
94. Luz I., Soukri M., Lail M., Confining metal–organic framework nanocrystals within mesoporous materials: a general approach via “solid-state” synthesis, Chemistry of Materials, 29 (2017) 9628–9638. DOI: 10.1021/acs.chemmater.7b0204210.1021/acs.chemmater.7b02042 ↗
95. Luz I., Stewart I.E., Mortensen N.P., Hickey A.J., Designing inhalable metal organic frameworks for pulmonary tuberculosis treatment and theragnostics via spray drying, Chemical Communications, 56 (2020) 13339–13342. DOI: 10.1039/D0CC05471B10.1039/D0CC05471B ↗
96. Luz I., Toy L., Rabie F., Lail M., Soukri M., Synthesis of soluble metal organic framework composites for mixed matrix membranes, ACS Applied Materials & Interfaces, 11 (2019) 15638–15645. DOI: 10.1021/acsami.9b0262210.1021/acsami.9b02622 ↗
97. Maa Y.F., Prestrelski S.J., Biopharmaceutical powders particle formation and formulation considerations, Current Pharmaceutical Biotechnology, 1 (2000) 283–302. DOI: 10.2174/138920100337889810.2174/1389201003378898 ↗
98. Manning T., Mikula R., Wylie G., Phillips D., Jarvis J., Zhang F., Structural measurements and cell line studies of the copper-PEG-Rifampicin complex against mycobacterium tuberculosis, Bioorganic & Medicinal Chemistry Letters, 25 (2015a) 451–458. DOI: 10.1016/j.bmcl.2014.12.05310.1016/j.bmcl.2014.12.053 ↗
99. Manning T., Patel H., Wylie G., Phillips D., Jarvis J., Structural measurements and cell line studies of the copper–PEG– Amikacin complex against Mycobacterium tuberculosis, Bioorganic & Medicinal Chemistry Letters, 25 (2015b) 5825–5830. DOI: 10.1016/j.bmcl.2015.08.01210.1016/j.bmcl.2015.08.012 ↗
100. Manning T.J., Wilkerson K., Holder T., Bartley A.C., Jackson C., Plummer S., Phillips D., Krajewski L., Wylie G., Pharmacokinetic studies of a three-component complex that repurposes the front line antibiotic isoniazid against Mycobacterium tuberculosis, Tuberculosis, 107 (2017) 149–155. DOI: 10.1016/j.tube.2017.08.01110.1016/j.tube.2017.08.011 ↗